The Stroke Ward at Manchester Royal Infirmary has a strong commitment to supporting research with the aim of improving future treatment for stroke patients.
We are currently supporting a variety of studies including:
Imaging cerebral neuroinflammation in acute and chronic cerebrovascular disease (IN-CVD)
The researchers at IN-CVD headquarters want to measure the swelling in the brain shortly after a patient has had a stroke. They are hoping to use the measurement to help predict the long-term effects of stroke using an imaging method called positron emission tomography (PET) with a new dye called [18F]GE-180.
The dye (also called a radiotracer) is a substance that is injected into your blood stream. This is in your body during the PET scan and helps to highlight areas within the body on the scan.
It is anticipated that the new dye will highlight the swollen areas in the brain. This will mean that we will be able to identify the amount of swelling around the damaged tissue.
ACST-2 Asymptomatic Carotid Surgery Trial 2
ACST-2 is a world-wide stroke prevention study comparing carotid endarterectomy (CEA) versus carotid artery stenting (CAS) in patients with asymptomatic carotid stenosis where there is substantial uncertainty as to which treatment is more appropriate.
For more information visit the ACST-2 website.
Motorised Rehabilitation of walking- MoRoW3
Researchers at the University of Manchester are working with NHS and other partners to develop a robot to help people learn to walk again after a stroke. The Motorised Rehabilitation of Walking (MoRoW-3) is funded by the National Institute of Health Research’s Invention for Innovation programme. It aims to support the patient’s weight and help them move their legs through a normal stepping movement pattern.
The 1st part of this project involves collecting measurements (height, leg length and circumference, hips and waist) from 500 stroke survivors to make sure Morow-3 accommodates the full range of body shapes and weights.
For more information about MoRoW3 please contact email@example.com / +44 (0)161 306 7335.